TB noon conference

1. Tuberculosis Miguel G. Madariaga, MD Assistant Professor of Medicine University of Nebraska Medical Center

2. Tuberculosis: an ancient scourge Lombardi, Rev Antropol Chil, 2000.

3. Famous people with tuberculosis *Those who died from tuberculosis

4. Tuberculosis : the myth

5. The last 150 years in the history of tuberculosis

6. Tuberculosis: the epidemiological chain

8. M. tuberculosis cell wall

9. The host

10. Tuberculosis transmission

11. Tuberculosis: the global picture

12. The impact of HIV on TB

13. The Kwa-Zulu Natal outbreak

14. Extensively drug resistant tuberculosis XDR TB is the occurrence of TB in persons whose M. tuberculosis isolates are resistant to isoniazid and rifampin plus resistant to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). CDC.

16. Pathogenesis of tuberculosis

17. The natural history and spectrum of tuberculosis

18. Primary pulmonary tuberculosis

19. Post-primary tuberculosis

20. Pathology of tuberculosis

22. Pleural tuberculosis Adenosine deaminase in pleural fluid

23. Lymph node tuberculosis

24. Genitourinary tuberculosis

25. Bone and joint tuberculosis

26. Peritoneal and digestive tract tuberculosis

27. Cerebral and meningeal tuberculosis

28. Miliary tuberculosis

29. The tuberculin skin test

30. Criteria for a positive TST

31. False positive and false negative results for TST

32. The booster effect in the elderly

33. Interferon gamma assays (QuantiFERON TB-Gold)

35. Getting a sputum sample

36. Ziehl-Nielsen stain

37. Culture

38. Radiology

39. Histopathological diagnosis

40. Fluorochrome staining (auramine)

42. Microscopic observation broth-drug susceptibility assay (MODS)

44. Prevention of resistance: the need for drug combinations

46. Treatment algorithm for tuberculosis

47. Approved combinations for the treatment of tuberculosis

48. First line TB drugs

49. Adverse reactions of first line drugs

50. Adverse reactions of first line drugs

52. Guidelines for TB retreatment

53. Antituberculosis agents available in US

54. Priority situations for the use of DOT

55. NNRTIs/TB meds: interactions

56. PIs/TB meds: interactions

59. Infection control

60. Treatment of latent tuberculosis

62. Tuberculosis in Nebraska